Thrombotic Thrombocytopenic Purpura Masquerading as Acute Ischemic Stroke by Kassar, Emily
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
4-13-2020 
Thrombotic Thrombocytopenic Purpura Masquerading as Acute 
Ischemic Stroke 
Emily Kassar 
Boca Raton Regional Hospital 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
Citation 
Cureus (2020) 12(4):e7661 
This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health 
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly 
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net. 
Received 07/22/2019 
Review began 03/23/2020 
Review ended 04/04/2020 
Published 04/13/2020
© Copyright 2020
Filatov et al. This is an open access
article distributed under the terms of
the Creative Commons Attribution
License CC-BY 4.0., which permits
unrestricted use, distribution, and
reproduction in any medium, provided
the original author and source are
credited.
Thrombotic Thrombocytopenic Purpura
Masquerading as Acute Ischemic Stroke
Asia Filatov  , Emily Kassar   , Oladipo Cole 
1. Neurology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, USA 2.
Internal Medicine, Edward Via College of Osteopathic Medicine, Auburn, USA 3. Internal Medicine, Boca
Raton Regional Hospital, Boca Raton, USA 4. Internal Medicine, Florida Atlantic University, Boca Raton ,
USA
Corresponding author: Asia Filatov, asia.filatov@gmail.com
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a hematologic disorder that results in
widespread clotting due to a deficiency of a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13 (ADAMTS13) protease. This leads to excessive von
Willebrand factor (VWF) protein-platelet multimers. Due to platelet consumption, platelet
levels fall, resulting in thrombocytopenia. We examined a case of a 31-year-old female with no
significant medical history who presented with expressive aphasia and paresthesias and was
sent to the Emergency Department for a stroke workup. Imaging was negative for ischemic or
hemorrhagic stroke; however, a complete blood count (CBC) was consistent with anemia and
thrombocytopenia, resulting in a high suspicion for TTP. She was admitted to the intensive care
unit and given fresh frozen plasma and packed red blood cells. Plasma exchange therapy was
initiated, and her aphasia and paresthesias began to improve. The ADAMTS13 level returned at
less than 5%, which prompted the initiation of rituximab therapy. During her 36-day hospital
stay, she continued to receive daily steroids and plasma exchange and a total of four courses of
rituximab. Her platelets steadily climbed, and she was discharged with instructions to follow up
with outpatient hematology. TTP is a thrombotic microangiopathy that results in microscopic
blood clots anywhere in the body, including the cerebral arteries. This results in the neurologic
abnormalities that are often seen in TTP. Because TTP is a rare disease, treatment modalities
are still scarce but include steroids, plasma exchange therapy, and rituximab. Novel therapies
are on their way, one being caplacizumab, a monoclonal antibody that inhibits VWF from
interaction with glycoprotein 1b. A concern highlighted by this case is the exclusion criteria for
the administration of tissue plasminogen activator (TPA). As this patient presented with stroke
symptoms and a negative head CT, TPA would have been administered had a CBC not returned
showing evidence of TTP. This highlights the importance of strict adherence to the American
Heart Association/American Stroke Association guidelines that include ensuring that the
platelet count is >100,000 prior to the initiation of TPA.
Categories: Neurology
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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare hematologic disorder causing
widespread clotting, resulting in low platelets. The disease results from a deficiency of the a
disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13
(ADAMTS13) protease, which results in excessive multimers of the von Willebrand factor
(VWF) protein-platelet complex attached to the vascular endothelium [1]. The classic pentad
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known as FATRN (fever, microangiopathic hemolytic anemia [MAHA], thrombocytopenia, renal
abnormalities, and neurologic symptoms) represents the disease in its most severe form [2].
Neurologic symptoms are most commonly headache and confusion, but in rare cases it can
present as seizures and focal deficits [2]. In the following section, we will examine a patient who
presented to her primary care physician with a complaint of upper respiratory symptoms along
with nausea, vomiting, diarrhea, and abdominal pain. During her visit, she began to exhibit
expressive aphasia and was sent to the Emergency Department (ED) for a stroke workup.
 
Case Presentation
A 31-year-old female with no significant medical history presented to the ED with garbled
speech that began just prior to arrival. In the days prior, she experienced viral upper respiratory
symptoms, as well as nausea, vomiting, diarrhea, and fatigue. Of note, she is an elementary
school teacher who is frequently exposed to contractible illness. Due to the persistence of her
symptoms, she saw her primary care physician. During the visit, she exhibited garbled speech
and was sent to the ED, where a stroke workup was initiated. Upon arrival, her altered speech
was still present, which included statements such as "I ate Benadryl for breakfast". She also
complained of paresthesias.
In the ED, the head CT was negative for acute intracranial findings (Figure 1).
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FIGURE 1: CT of the head: normal findings and no intracranial
pathology.
She was febrile with a temperature of 38.1 degrees Celsius. The possibility of initiating tissue
plasminogen activator (TPA) for acute ischemic stroke was discussed; however, complete blood
count (CBC) was returned with a hemoglobin of 6.6, a mean corpuscular volume (MCV) of 93 fL,
and a platelet count of 4,000. As the patient had neurologic symptoms with anemia and
thrombocytopenia in the setting of viral illness, TTP and hemolytic uremic syndrome (HUS)
were included in the differential diagnosis. She was admitted to the intensive care unit and
further workup was initiated. A peripheral smear was performed and showed schistocytes. LDH
(lactate dehydrogenase) was elevated at 1,154 and haptoglobin was decreased at <8, indicative
of intravascular hemolysis [3]. An ADAMTS13 level assay was ordered. Since this test takes
several days to return, her PLASMIC score was assessed using several variables including
platelet count, MCV, and INR (international normalized ratio) to calculate the probability of
severe ADAMTS13 deficiency [4]. Her score was 6, as shown in Table 1, indicating a high risk of
severe ADAMTS13 deficiency [4]. 




Platelet count < 30 x 109/L 4 x 109/L 1
Hemolysis (indirect bilirubin > 2 mg/dL, uncorrected reticulocyte count >




No active cancer in the previous year 
No active cancer in the previous
year
1
No history of solid organ or stem cell transplant
No history of solid organ or stem
cell transplant
1
Mean corpuscular volume < 90 Mean corpuscular volume: 93 0
International normalized ratio < 1.5 International normalized ratio: 1.1 1
Creatinine < 2 mg/dL 0.8 1
Total: 6
TABLE 1: Components of PLASMIC score and patient data.
A hematologist was consulted. Eight hours after arrival to the ED, she received 4 units of fresh
frozen plasma, 2 units of packed red blood cells and two courses of plasmapheresis, resulting in
a rapid resolution of aphasia and paresthesias. Her MRA (magnetic resonance angiography) was
negative for an embolic event, ruling out ischemic stroke (Figure 2). An infectious workup,
which included HIV (human immunodeficiency virus), stool Shiga toxin, mycoplasma, and
Epstein-Barr virus, was negative. Her antinuclear antibody was within the normal limits,
excluding rheumatologic causes. She was started on steroids and continued to receive daily
courses of plasmapheresis. Her ADAMTS13 level returned at less than 5%, confirming TTP, and
the decision to start rituximab was made. She received weekly therapy with a total of four
treatments during her hospital stay. Plasmapheresis was performed daily, excluding the days
that she received rituximab. From a hematologic perspective, she was initially slow to respond.
Her platelet count climbed very slowly, with transient dips throughout her hospital stay. The
patient continued to be examined by a neurologist and a hematologist. After a 36-day hospital
stay, she was discharged with a platelet count of just over 200,000 and a hemoglobin of 10.2.
She was placed on daily prednisone and instructed to follow up with outpatient hematology,
including weekly bloodwork.
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FIGURE 2: MRA of the brain: normal, negative for an embolic
event.
MRA, magnetic resonance angiography
Discussion
The pathophysiology of TTP is based on the ADAMTS13 protease, which cleaves the VWF
multimer. VWF is a protein-platelet complex essential in creating a platelet plug at the
endothelium of injured vessels [1]. In the acquired form of the disease, autoantibodies are
produced against the ADAMST3 protease, which results in persistent VWF multimers and
systemic thromboses. Platelet counts decrease as platelets are consumed causing
thrombocytopenia. MAHA in TTP results from shearing forces as red blood cells travel across
platelet clumps on the vascular endothelium. MAHA in TTP results from shearing forces as red
blood cells travel across platelet clumps on the vascular endothelium, producing fragmented
red blood cells known as schistocytes.
Expressive aphasia is an example of neurologic manifestation occurring in TTP resulting from
brain damage, particularly the areas concerned with language. Consequently, the patient's
speech production gets severely damaged, even though his or her intellect might be intact. The
usual cause of aphasia is brain injury or stroke, which damages one or more areas of the brain
dealing with language. In most cases, neurologic symptoms including expressive aphasia occur
in the course of TTP [3]. This argument is based on the interaction between the circulating
platelets and the vascular endothelium that results in a profound dysregulation of coagulation.
CT scan of these patients may demonstrate infarcts in specific sections of the brain that
correlate with neurologic findings including expressive aphasia [1].
Research studies have demonstrated incidences of atypical TTP in patients with strokes. Idowu
and Reddy present a case of a middle-aged woman with atypical thrombocytopenic purpura
who presented with an inability to speak, mild dysarthria, and expressive aphasia [5]. The
patient showed marked improvement in her neurologic status upon receiving seven TPEs. Crum
and O'Brien in their research article reported two TTP cases where initial findings majorly
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comprised neurologic deficits including expressive aphasia, hence causing delays in diagnosis
[6]. These neurologic deficits were later followed by hematologic manifestations. A research
study by Boattini and Procaccianti has also shown that TTP is commonly associated with
abnormal brain neuroimaging and that therapeutic plasma exchange (PEX) is useful in
resolving the symptoms [7]. A case report by Azmi and Maizuliana of a 38-year-old lady who
presented with TTP, expressive aphasia, and right-sided body weakness also shows that these
symptoms may commonly occur together [8].TTP is a hematologic condition that is described
by a pentad of neurologic and renal abnormalities, fever, anemia, and thrombocytopenia.
Patients with TTP in most cases present with neurologic deficits; however, expressive aphasia
is rare, hence requiring further investigations to ensure effective management.
The diagnostic test for TTP is an ADAMTS13 assay, which expresses ADAMTS13 activity as a
fraction of normal activity within pooled plasma [9]. Given that ADAMTS13 assay takes several
days to return, a preliminary diagnosis can be made clinically if the patient presents with
MAHA and thrombocytopenia without another known cause and without acute renal failure. If
acute renal failure is present, HUS is more likely. A PLASMIC score, as was calculated in our
patient, is often used to determine the probability that severe ADAMTS13 protease deficiency
is present based on several clinical findings, with 1 point assigned to each. In 2018, a study
evaluated the success of PEX therapy in patients with low intermediate (0-5) risk scores and
high (6-7) risk scores [4]. In the high-risk group, treatment with PEX therapy leads to
significantly increased survival [4]. With a PLASMIC score of 6, the present patient is
considered at high risk, and PEX was conducted prior to the return of an ADAMTS13 level assay.
TTP is a recognized rare disease according to the National Heart, Lung, and Blood Institute, a
center part of the National Institutes of Health. As with many rare diseases, treatment
modalities are scarce, but novel studies are underway [10]. In the subsequent paragraphs, the
accepted treatment guidelines are reviewed, in addition to other treatment modalities used in
refractory cases as well as novel biologics being studied currently.
The recognized guideline treatment for TTP is plasmapheresis or PEX for acquired TTP or
plasma therapy for inherited TTP. For inherited TTP, plasma therapy is instituted to replace the
ADAMTS13 enzyme [7,10-13]. In acquired TTP, PEX is used to remove anti-ADAMTS13 enzyme
antibody and to replete the enzyme itself. A once fatal process now has a survival benefit of up
to 85% using PEX [12,13]. As soon as a diagnosis is made or suspect TTP, PEX should be
initiated at 1.5x plasma volume exchange for the first procedure and 1.0x plasma volume
exchange for subsequent treatments. This process is performed until platelet concentration
reaches normal levels, organ involvement has resolved, and hemolysis has terminated [8,13].
Steroids are often the mainstay of treating autoimmune disease such as
immune thrombocytopenia, systemic lupus erythematosus, and Sjogren’s syndrome to name a
few. However, evidence of its effectiveness in treating TTP is minimal at best. Coppo and
French Reference Center for Thrombotic Microangiopathies evaluated the outcomes in various
studies and concluded that steroids given in combination with PEX versus PEX alone were
equivalent [11-13]. Furthermore, it has been observed that relapse occurs more frequently with
steroid treatment. Nevertheless, current guidelines recommend the initiation of systemic
steroids of 1.5 mg/kg/day for three weeks, which is quite reasonable [12]. Some studies even
suggest using high-dose methylprednisolone (10 mg/kg/day for three days followed by 2.5
mg/kg/day) as an adjunctive treatment with PEX for patients with new-onset TTP, achieving a
modest 78% remission after 23 days of treatment in a small study [13].
Rituximab is an anti-CD20 monoclonal antibody originally developed to treat B cell
malignancies [7,13]. However, several trials have shown its effective properties and high
response to treat TTP, and it has now become the mainstay first-line treatment in both the
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acute phase and refractory cases (i.e., exacerbations or no improvement in clinical features or
lack of platelet response within four days of PEX) and has led to remission in one to four weeks
in patients [7,11-13]. For acute cases, two prospective trials resulted in shorter hospitalization
and fewer relapses in patients who did not respond optimally to PEX. As with other treatments
discussed below, targeting the inhibition in the production of anti-ADAMTS13 antibody with
four infusions at 375 mg/m2/week after PEX is the goal using rituximab. This therapy quickly
reduces peripheral antibody-producing B cells, thus causing a rapid and substantial reduction
in anti-ADAMTS13 antibody. Remissions have been significant within the first year of therapy.
These are considerably significant when compared with other modalities of therapies.
Cyclosporine and vincristine have historically been used in refractory TTP. Both of these agents
have been reported to have a steady remission rate in refractory TTP, up to 73%, and in some
instances are being used as frontline agents in a small subset of patients, when response to PEX
is inadequate. Nevertheless, the literature and specialists consider these choices as secondary
or salvage therapy after rituximab [8,13]. These two agents have suppressive properties of the
anti-ADAMTS13 antibody. However, novel randomized studies have resulted in a more
significant response, with steroids decreasing the serum concentration of anti-ADAMTS13
antibody, questioning these two agents’ utility in treatment.
Rare diseases such as TTP are on the path of achieving medical breakthroughs with novel
antigen/antibody-targeted treatment modalities. caplacizumab, an inhibitor of VWF-
glycoprotein 1b interaction (formerly ALX-0081), may pave the way for the HERCULES trial,
which is a phase III double-blind placebo-controlled study which is using caplacizumab to show
promising results. Significant results such as shorter time to platelet recovery, decrease in
ischemic organ dysfunction through inflammatory biomarkers, and reduction in the incidence
of exacerbations are paving the way to make this drug quite promising.
One concern highlighted by this case is the exclusion criteria for TPA administration in a
patient presenting with neurologic deficits and a negative head CT. According to the American
Heart Association (AHA) and the American Stroke Association (ASA) guidelines, the inclusion
criteria for initiation of TPA includes a clinical diagnosis of ischemic stroke with neurologic
deficit, time from symptom onset between 3 and 4.5 hours, and no absolute
contraindications [14]. As per the ASA/AHA, a platelet count of <100,000 is an absolute
contraindication, and a CBC is required as part of immediate testing in a patient with stroke
symptoms [14].
A retrospective cohort study published in 2015 examined the importance of awaiting the results
of a CBC prior to initiating TPA. The study population consisted of patients receiving TPA in a
hospital in both China and the United States and showed that a significantly shorter door-to-
needle interval was found in a group of patients who received TPA prior to the return of CBC
results [13]. Additionally, of the patients who received TPA before CBC was returned, 98.8% of
patients had normal results [13]. The remaining patient had a platelet count of 88,000, and no
adverse event occurred from TPA administration. Applying the results of this study would have
been catastrophic in our patient and raises several pertinent questions: if time is of the essence
and we cannot wait for a CBC to return, how often would we be causing a negative outcome,
most importantly, intracranial hemorrhage? In a patient with no risk factors for ischemic
stroke, including young age and no significant medical history, should we be concerned for a
hematologic cause and wait for a CBC even if we risk closing the window for TPA
administration?
Conclusions
TTP is an autoimmune condition that affects the coagulation system, resulting in the formation
of microscopic blood clots in any blood vessel such as the cerebral arteries. Clinical
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presentation of TTP occurs due to end-organ damage and reduced blood flow. Neurologic
manifestations such as expressive aphasia, altered mental status, visual disturbances, seizures,
and paresthesia can often be experienced by these patients as a result of cerebral ischemia
caused by microscopic clots occurring in the cerebral arteries. Patients with TTP can present to
the emergency setting in the same manner as patients with an acute stroke with negative CT
imaging. This can prompt physicians to treat these patients as ischemic stroke patients and
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